NCT06788431View on ClinicalTrials.gov

A Study Evaluating the Stability and Efficacy of IMC-001 for Injection on Atherosclerotic Plaques in Patients With ACS.

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Atherosclerosis
Interventions
DRUG

IMC-001 and Optimal medical treatment

Subjects receive IMC-001 administered by injection once a week for 13 weeks and also receive optimal medical treatment.

DRUG

IMC-001 placebo and optimal medical treatment

Subjects receive IMC-001 placebo administered by injection once a week for 13 weeks and also receive optimal medical treatment.

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital of Nanyang Medical College, Nanyang

RECRUITING

Renji Hospital,Shanghai, Shanghai

All Listed Sponsors
collaborator

RenJi Hospital

OTHER

collaborator

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

OTHER

collaborator

The First Affiliated Hospital of Nanyang Medical College

UNKNOWN

lead

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

OTHER

NCT06788431 - A Study Evaluating the Stability and Efficacy of IMC-001 for Injection on Atherosclerotic Plaques in Patients With ACS. | Biotech Hunter | Biotech Hunter